| Citation: |
ZHAO Zhengqiang, CHEN Long, LIU Yujie, TIAN Suqing. Prognosis-related Factors of Colorectal Cancer Patients with Positive PD-L1 Expression in Liver Metastases After Hepatectomy[J]. Cancer Research on Prevention and Treatment, 2021, 48(8): 782-787. DOI: 10.3971/j.issn.1000-8578.2021.21.0124
|
To evaluate the prognosis-related factors of colorectal cancer patients with positive PD-L1 expression in liver metastases after hepatectomy.
We reviewed retrospectively the clinical data of 68 colorectal cancer patients with positive PD-L1 expression in liver metastases receiving personalized comprehensive treatment which was mainly consisted of surgical resection. We observed the results and prognosis after surgical resection and analyzed related factors.
Univariate analysis showed that no radiotherapy, N stage, RAS mutation status, T stage, dMMR, Duck stage, disease free interval from primary to metastases≤12 months and largest hepatic tumor diameter > 5 cm had obvious significance (all P < 0.05). Multivariate logistic analysis regression revealed that without dMMR (P=0.012), Duck A stage (P=0.000), disease free interval from primary to metastases > 12 months (P=0.020) and largest hepatic tumor diameter < 5 cm (P=0.006) were independent protective factors for the prognosis of colorectal cancer patients with positive PD-L1 expression in liver metastases after surgical resection.
Personalized comprehensive treatment which is mainly consisted of surgical resection still has a good effect on colorectal cancer patients with positive PD-L1 expression in liver metastases after hepatectomy. Without dMMR, Duck A stage, disease free interval from primary to metastases > 12 months and largest hepatic tumor diameter ≤5cm are independent protective factors for patients' prognosis.
Competing interests: The authors declare that they have no competing interests.
| [1] |
熊振芳. PD-L1调控结直肠癌增殖及侵袭转移机制的研究[D]. 南昌: 南昌大学, 2017.
Xiong ZF. Study on the mechanism of PD-L1 regulating the proliferation and metastasis of colorectal carcinoma[D]. Nanchang: Nanchang University, 2017.
|
| [2] |
冯昌银, 郑巧灵, 黄建平, 等. 结直肠癌肿瘤原发灶与肝脏转移灶中PD-L1表达的差异性[J]. 临床与实验病理学杂志, 2018, 34(12): 1340-1344. https://www.cnki.com.cn/Article/CJFDTOTAL-LSBL201812012.htm
Feng CY, Zheng QL, Huang JP, et al. Diffrential expression of PD-L1 between primary and hepatic metastases of colorectal cancer[J]. Lin Chuang Yu Shi Yan Bing Li Xue Za Zhi, 2018, 34(12): 1340-1344. https://www.cnki.com.cn/Article/CJFDTOTAL-LSBL201812012.htm
|
| [3] |
宋天强. 同时性结直肠癌肝转移的治疗策略[J]. 中华肝胆外科杂志, 2020, 26(10): 725-729. doi: 10.3760/cma.j.cn113884-20200716-00374
Song TQ. Treatment strategy of synchronous colorectal cancer liver metastases[J]. Zhonghua Gan Dan Wai Ke Za Zhi, 2020, 26(10): 725-729. doi: 10.3760/cma.j.cn113884-20200716-00374
|
| [4] |
王飞, 武健. 同时性结直肠癌肝转移的治疗进展[J]. 沈阳医学院学报, 2018, 20(2): 166-169. https://www.cnki.com.cn/Article/CJFDTOTAL-SYYX201802022.htm
Wang F, Wu J. Research Progress in the Treatment of Synchronous Colorectal Liver Metastasis[J]. Shenyang Yi Xue Yuan Xue Bao, 2018, 20(2): 166-169. https://www.cnki.com.cn/Article/CJFDTOTAL-SYYX201802022.htm
|
| [5] |
Ihnát P, Vávra P, Zonča P. Treatment strategies for colorectal carcinoma with synchronous liver metastases: Which way to go?[J]. World J Gastroenterol, 2015, 21(22): 7014-7021. doi: 10.3748/wjg.v21.i22.7014
|
| [6] |
Venderbosch S, Nagtegaal ID, Maughan TS, et al. Mismatch repair status and BRAF mutation status in metastatic colorectal cancer patients: A pooled analysis of the CAIRO, CAIRO2, COIN, and FOCUS studies[J]. Clin Cancer Res, 2014, 20(20): 5322-5330. doi: 10.1158/1078-0432.CCR-14-0332
|
| [7] |
Valentini AM, Di Pinto F, Cariola F, et al. PD-L1 expression in colorectal cancer defines three subsets of tumor immune microenvironments[J]. Oncotarget, 2018, 1(9): 8584-8596. http://europepmc.org/articles/PMC5823560/
|
| [8] |
Llosa NJ, Cruise M, Tam A, et al. The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints[J]. Cancer Discov, 2015, 5(1): 43-51. https://pubmed.ncbi.nlm.nih.gov/25358689/
|
| [9] |
刘佳明, 刘伟, 徐达, 等. RAS基因突变对结直肠癌肝转移患者肝切除术后预后的影响[J]. 中华肝胆外科杂志, 2020, 26(1): 1-5. doi: 10.3760/cma.j.issn.1007-8118.2020.01.001
Liu JM, Liu W, Xu D, et al. Impact of mutant RAS on prognosis of patients after hepatic resection for colorectal cancer liver metastases[J]. Zhonghua Gan Dan Wai Ke Za Zhi, 2020, 26(1): 1-5. doi: 10.3760/cma.j.issn.1007-8118.2020.01.001
|
| [10] |
Vauthey JN, Zimmitti G, Kopetz SE, et al. RAS mutation status predicts survival and patterns of recurrence in patients undergoing hepatectomy for colorectal liver metastases[J]. Ann Surg, 2013, 258(4): 619-627. doi: 10.1097/SLA.0b013e3182a5025a
|
| [11] |
Schirripa M, Bergamo F, Cremolini C, et al. BRAF and RAS mutations as prognostic factors in metastatic colorectal cancer patients undergoing liver resection[J]. Br J Cancer, 2015, 112(12): 1921-1928. doi: 10.1038/bjc.2015.142
|
| [12] |
Méndez Romero A, Keskin-Cambay F, van Os RM, et al. Institutional experience in the treatment of colorectal livermetastases with stereotactic body radiation therapy[J]. Rep Pract Oncol Radiother, 2017, 22(2): 126-131. doi: 10.1016/j.rpor.2016.10.003
|
| [13] |
罗德庆. 淋巴结转移率与Ⅲ期结肠癌患者预后的关系[D]. 广州: 广州医科大学, 2018.
Luo DQ. Lymph node ratio with prognosis of stage Ⅲ colon cancer[D]. Guangzhou: Guangzhou Medical University, 2018.
|
| [14] |
闫晓峦, 王崑, 包全, 等. 结直肠癌肝转移手术治疗预后及影响因素分析[J]. 中华肝胆外科杂志, 2020, 26(7): 508-513. doi: 10.3760/cma.j.cn113884-20200421-00216
Yan XL, Wang K, Bao Q, et al. Prognosis and risk factors after surgical treatment for colorectal cancer liver metastases[J]. Zhonghua Gan Dan Wai Ke Za Zhi, 2020, 26(7): 508-513. doi: 10.3760/cma.j.cn113884-20200421-00216
|
| [15] |
解彤彤, 胡静, 杨觅, 等. PD-1/PD-L1在dMMR/MSI-H结直肠癌患者临床试验中的研究进展[J]. 现代肿瘤医学, 2019, 27(5): 885-888. doi: 10.3969/j.issn.1672-4992.2019.05.042
Xie TT, Hu J, Yang M, et al. Progression of the research on PD-1/PD-L1 in dMMR/MSI-H colorectal cancer[J]. Xian Dai Zhong Liu Yi Xue, 2019, 27(5): 885-888. doi: 10.3969/j.issn.1672-4992.2019.05.042
|
| [16] |
黄哲, 李开艳, 周萍萍, 等. 结直肠癌肝转移超声引导下经皮微波消融与手术切除疗效的对比分析[J]. 中华医学杂志, 2020, 100(9): 696-701. doi: 10.3760/cma.j.issn.0376-2491.2020.09.010
Huang Z, Li KY, Zhou PP, et al. Comparative study of ultrasound-guided percutaneous microwave ablation and surgical resection for colorectal cancer with liver metastasis[J]. Zhonghua Yi Xue Za Zhi, 2020, 100(9): 696-701. doi: 10.3760/cma.j.issn.0376-2491.2020.09.010
|
| [17] |
Gatalica Z, Vranic S, Xiu J, et al. High microsatellite instability(MSI-H) colorectal carcinoma: A brief review of predictive biomarkers in the era of personalized medicine[J]. Fam Cancer, 2016, 15(3): 405-412. doi: 10.1007/s10689-016-9884-6
|
| [18] |
Llosa NJ, Cruise M, Tam A, et al. The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter inhibitory checkpoints[J]. Cancer Discov, 2015, 5(1): 43-51. https://pubmed.ncbi.nlm.nih.gov/25358689/
|
| [19] |
蒋微琴, 陈功. 初始可切除的结直肠癌肝转移新辅助治疗的价值[J]. 肝胆胰外科杂志, 2019, 31(4): 203-207. https://www.cnki.com.cn/Article/CJFDTOTAL-GDYW201904004.htm
Jiang WQ, Chen G. The value of neoadjuvant therapy for initial resectablecolorectal cancer with liver metastasis[J]. Gan Dan Yi Wai Ke Za Zhi, 2019, 31(4): 203-207. https://www.cnki.com.cn/Article/CJFDTOTAL-GDYW201904004.htm
|
| [20] |
曹奇华, 许燕波, 徐栋. 结直肠癌免疫检查点治疗的研究进展[J]. 肿瘤防治研究, 2021, 48(3): 229-233. doi: 10.3971/j.issn.1000-8578.2021.20.1060
Cao QH, Xu YB, Xu D. Research progress of immune checkpoint therapy on colorectal cancer[J]. Zhong Liu Fang Zhi Yan Jiu, 2021, 48(3): 229-233. doi: 10.3971/j.issn.1000-8578.2021.20.1060
|
| [21] |
Tejpar S, Stintzing S, Ciardiello F, et al. Prognostic and predictive relevance of primary tumor location in patients with RAS wildtype metastatic colorectal cancer: retrospective analyses of the CRYSTAL and TIRE-3 trials[J]. JAMA Oncol, 2017, 3(2): 194-201. doi: 10.1001/jamaoncol.2016.3797
|
Tables(2)
This work is licensed under a Creative Commons Attribution 3.0 License.
Copyright © Editorial Department of Cancer Prevention Research 鄂公网安备 42011102005013号 鄂ICP备2022015867号
Supported by: Beijing Renhe Information Technology Co., Ltd. 
DownLoad: